Functional polymorphisms in FAS, FASL and CASP8 genes and risk of childhood acute lymphoblastic leukemia: A case-control study

Leukemia and Lymphoma

Volumn 53, Issue 7, 2012, Pages 1360-1366

  Tong, Na ^a   Zhang, Limei ^a   Sheng, Xiaojing ^a   Wang, Meilin ^a   Zhang, Zhizhong ^a   Fang, Yongjun ^a   Xue, Yao ^a   Li, Jie ^b   Zhang, Zhengdong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

CASP8; FAS; FASL; leukemia; polymorphisms

Indexed keywords

CASPASE 8; FAS ANTIGEN; FAS LIGAND;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALCOHOL CONSUMPTION; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHILD; CHILDHOOD CANCER; CHINESE; CONTROLLED STUDY; DNA POLYMORPHISM; DRINKING BEHAVIOR; ENVIRONMENTAL FACTOR; FEMALE; GENE DELETION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; GENOTYPE ENVIRONMENT INTERACTION; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PAINTING; PARENTAL BEHAVIOR; PHENOTYPE; PRIORITY JOURNAL; SMOKING;

ALLELES; ANTIGENS, CD95; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CASPASE 8; CHILD; CHILD, PRESCHOOL; CHINA; FAS LIGAND PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; POLYMORPHISM, GENETIC; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RISK FACTORS;

EID: 84862731740     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.654117     Document Type: Article

References (35)

1. Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000;12:3-12. (Pubitemid 32046831)
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics. 2008. CA Cancer J Clin 2008;58:71-96.
3. Rampersaud GC, Kauwell GP, Bailey LB. Folate: a key to optimizing health and reducing disease risk in the elderly. J Am Coll Nutr 2003;22:1-8. (Pubitemid 36164452)
4. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003;193:70-81. (Pubitemid 36688041)
5. Maher S, Toomey D, Condron C, et al. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002;80:131-137. (Pubitemid 34298085)
6. Chappell DB, Restifo NP. T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother 1998;47:65-71. (Pubitemid 28442705)
7. Aggarwal BB. Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunol 2003;3:745-756. (Pubitemid 41070815)
8. Suda T, Takahashi T, Golstein P, et al. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178. (Pubitemid 24006113)
9. Siegel RM. Caspases at the crossroads of immune-cell life and death. Nat Rev Immunol 2006;6:308-317.
10. Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577-582. (Pubitemid 27512871)
11. Sibley K, Rollinson S, Allan JM, et al. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327-4330. (Pubitemid 36950998)
12. Wu J, Metz C, Xu X, et al. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132-138. (Pubitemid 36026132)
13. Ho PK, Hawkins CJ. Mammalian initiator apoptotic caspases. FEBS J 2005;272:5436-5453. (Pubitemid 41581660)
14. Sun T, Gao Y, Tan W, et al. A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 2007;39:605-613. (Pubitemid 46676113)
15. Zhang Z, Qiu L, Wang M, et al. The FAS ligand promoter polymorphism, rs763110 (-844C > T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009;17:1294-1303.
16. Zhang Z, Wang LE, Sturgis EM, et al. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:5596-5602. (Pubitemid 44497278)
17. Zhang X, Miao X, Sun T, et al. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479-484. (Pubitemid 40847235)
18. Wang LE, Cheng L, Spitz MR, et al. Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer 2003;42:1-8. (Pubitemid 37153130)
19. Ueda M, Hung YC, Terai Y, et al. Fas gene promoter -670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005;98:129-133. (Pubitemid 40826429)
20. Nelson HH, Kelsey KT, Bronson MH, et al. Fas/APO-1 promoter polymorphism is not associated with non-melanoma skin cancer. Cancer Epidemiol Biomarkers Prev 2001;10:809-810. (Pubitemid 32695162)
21. Tong N, Fang Y, Li J, et al. Methylenetetrahydrofolate reductase polymorphisms, serum methylenetetrahydrofolate reductase levels, and risk of childhood acute lymphoblastic leukemia in a Chinese population. Cancer Sci 2010;101:782-786.
22. Li C, Wu W, Liu J, et al. Functional polymorphisms in the promoter regions of the FAS and FAS ligand genes and risk of bladder cancer in south China: a case-control analysis. Pharmacogenet Genomics 2006;16:245-251.
23. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456-1462.
24. Griffith TS, Brunner T, Fletcher SM, et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995;270:1189-1192.
25. Shimonishi T, Isse K, Shibata F, et al. Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology 2000;32:761-769.
26. Chopin D, Barei-Moniri R, Maille P, et al. Human urinary bladder transitional cell carcinomas acquire the functional Fas ligand during tumor progression. Am J Pathol 2003;162:1139-1149. (Pubitemid 36350659)
27. Li C, Larson D, Zhang Z, et al. Polymorphisms of the FAS and FAS ligand genes associated with risk of cutaneous malignant melanoma. Pharmacogenet Genomics 2006;16:253-263.
28. Sun T, Miao X, Zhang X, et al. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030-1036. (Pubitemid 39162646)
29. Erdogan M, Karadeniz M, Berdeli A, et al. Fas/Fas ligand gene polymorphism in patients with papillary thyroid cancer in the Turkish population. J Endocrinol Invest 2007;30:411-416. (Pubitemid 47103003)
30. Yang M, Sun T, Wang L, et al. Functional variants in cell death pathway genes and risk of pancreatic cancer. Clin Cancer Res 2008;14:3230-3236.
31. Zhang H, Sun XF, Synnerstad I, et al. Importance of FAS-1377, FAS-670, and FASL-844 polymorphisms in tumor onset, progression, and pigment phenotypes of Swedish patients with melanoma: a case-control analysis. Cancer J 2007;13:233-237.
32. Zhang Z, Xue H, Gong W, et al. FAS promoter polymorphisms and cancer risk: a meta-analysis based on 34 case-control studies. Carcinogenesis 2009;30:487-493.
33. Pang D, McNally R, Birch JM. Parental smoking and childhood cancer: results from the United Kingdom Childhood Cancer Study. Br J Cancer 2003;88:373-381. (Pubitemid 36308147)
34. Lee KM, Ward MH, Han S, et al. Paternal smoking, genetic polymorphisms in CYP1A1 and childhood leukemia risk. Leuk Res 2009;33:250-258.
35. Freedman DM, Stewart P, Kleinerman RA, et al. Household solvent exposures and childhood acute lymphoblastic leukemia. Am J Public Health 2001;91:564-567. (Pubitemid 32245295)